Open AccessEfficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials
Author(s) -
Susan J. Tofte,
Kim Papp,
Neil S. Sadick,
Krista Bohnert,
Eric L. Simpson,
Diamant Thaçi,
Thomas Bieber,
Andrew Blauvelt,
Howard Sofen,
Melinda Gooderham,
Zhe Chen,
Abhijit Gadkari,
Laurent Eckert,
Neil M.H. Graham,
Gianluca Pirozzi,
Marius Ardeleanu
Publication year - 2018
Publication title -
journal of the american association of nurse practitioners
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.414
H-Index - 19
eISSN - 2327-6886
pISSN - 2327-6924
DOI - 10.1097/jxx.0000000000000088
Subject(s) - dupilumab , atopic dermatitis , medicine , scorad , placebo , eczema area and severity index , dermatology , visual analogue scale , clinical trial , dermatology life quality index , physical therapy , pathology , disease , alternative medicine
There is a need for new treatment options for moderate-to-severe atopic dermatitis (AD) in adults. Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody, has recently been approved for this indication.